Edition:
United States

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

12.13USD
23 Feb 2018
Change (% chg)

$0.17 (+1.42%)
Prev Close
$11.96
Open
$12.05
Day's High
$12.21
Day's Low
$11.83
Volume
32,828
Avg. Vol
47,709
52-wk High
$19.50
52-wk Low
$10.26

Select another date:

Thu, Feb 1 2018

BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22

* JAMES FLYNN REPORTS 5.1 PERCENT PASSIVE STAKE IN OXFORD IMMUNOTEC GLOBAL PLC AS OF JANUARY 22 - SEC FILING Source text: [http://bit.ly/2BNPx1n] Further company coverage:

BRIEF-Oxford Immunotec Announces Preliminary Revenue For Q4

* FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S

Qiagen to pay Oxford Immunotec $27.5 million to settle patent case

Qiagen NV said on Friday it had agreed to pay $27.5 million to resolve a lawsuit claiming that a tuberculosis blood test it produces infringes patents held by competitor Oxford Immunotec Global PLC.

BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit

* OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS

BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​

* Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​

BRIEF-Oxford Immunotec Global Q3 loss per share $0.70

* Oxford Immunotec reports third quarter 2017 financial results

Oxford Immunotec loses bid to block rival's blood test on patent grounds

By Nate Raymond A federal judge has declined to block Qiagen NV from bringing to market a blood test used to detect tuberculosis that competitor Oxford Immunotec Global PLC contends infringes patents on its own diagnostic kit.

BRIEF-Oxford Immunotec announces update in patent infringement litigation

* Oxford Immunotec announces update in patent infringement litigation

BRIEF-Oxford Immunotec updates on amendment to supply agreement with StemCell Technologies ​

* Oxford Immunotec Global PLC - ‍on Sept 1 unit entered into second amendment to supply agreement with StemCell Technologies Canada f/k/a StemCell Technologies ​

BRIEF-Oxford Immunotec appoints Stefan Linn as COO

* Oxford Immunotec appoints Stefan Linn as chief operating officer Source text for Eikon: Further company coverage:

Select another date: